<?xml version="1.0" encoding="UTF-8"?>
<list>
  <sentences>
    <s path="[OANC]/data/written_2/technical/biomed/1471-2253-2-5.anc" start="43720" end="43725" sStart="43717" offset="3" sid="r7.1.use.v.0130" wn="1" wnkey="use%2:34:01::" text="By using all the previous information that is available to restrict the model and minimize the number of adjustable parameters, PKQuest greatly increases the predictive power of the analysis." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2253-2-5.anc" start="16463" end="16467" sStart="null" offset="97" sid="r7.1.use.v.0176" wn="1" wnkey="use%2:34:01::" text="The PKQuest global (simulated annealing) and local (Powell) optimization routines were used to select the fat blood flow that provided the best fit to the enflurane data." />
    <s path="file:/c:/OANC/data/written_2/technical/biomed/1471-2253-2-5.anc" start="28174" end="28178" sStart="null" offset="0" sid="null" wn="7" wnkey="time%1:28:03::" text="Some of the most comprehensive and sophisticated human PBPKs have been developed to describe the pharmacokinetics of volatile toxic solvents such as toluene [ 32 44 45 ] , styrene [ 46 47 ] , and methyl chloride [ 48 ] . The most involved models incorporate several different fat and muscle compartments with different flows and allow for changes with &lt;b&gt;time&lt;/b&gt; in the blood flows as the subject's exercise level varies [ 45 47 48 ] . These studies have also introduced a Bayesian approach to determine the population distribution of the PBPK parameters [ 45 47 ] . PKQuest cannot complete with these PBPKs for this class of solutes." />
    <s path="file:/c:/OANC/data/written_2/technical/biomed/1471-2253-2-5.anc" start="28174" end="28178" sStart="null" offset="0" sid="null" wn="8" wnkey="time%1:28:04::" text="Some of the most comprehensive and sophisticated human PBPKs have been developed to describe the pharmacokinetics of volatile toxic solvents such as toluene [ 32 44 45 ] , styrene [ 46 47 ] , and methyl chloride [ 48 ] . The most involved models incorporate several different fat and muscle compartments with different flows and allow for changes with &lt;b&gt;time&lt;/b&gt; in the blood flows as the subject's exercise level varies [ 45 47 48 ] . These studies have also introduced a Bayesian approach to determine the population distribution of the PBPK parameters [ 45 47 ] . PKQuest cannot complete with these PBPKs for this class of solutes." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2253-2-5.anc" start="45921" end="45928" sStart="null" offset="0" sid="null" wn="4" wnkey="read%2:31:06::" text="ventilation) during uptake and washout or an error in &lt;b&gt;reading&lt;/b&gt; the data off the published linear plot." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2253-2-5.anc" start="10943" end="10947" sStart="null" offset="0" sid="null" wn="4" wnkey="read%2:31:06::" text="The experimental data points were obtained by using UN-SCAN-IT (Silk Scientific Corporation) to &lt;b&gt;read&lt;/b&gt; the data from the published figures (figs." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2253-2-5.anc" start="18082" end="18086" sStart="null" offset="0" sid="null" wn="2147483644" wnkey="null" text="ninput:=1; finput [ 1 ] :=table([organ=lung, type=1, &lt;b&gt;rate&lt;/b&gt;=0." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2253-2-5.anc" start="18082" end="18086" sStart="null" offset="0" sid="null" wn="1" wnkey="rate%1:28:00::" text="ninput:=1; finput [ 1 ] :=table([organ=lung, type=1, &lt;b&gt;rate&lt;/b&gt;=0." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2253-2-5.anc" start="27658" end="27662" sStart="null" offset="25" sid="r7.poor.j.0232" wn="5" wnkey="poor%5:00:00:insufficient:00" text="The explanation for this poor fit is provided in the Discussion section." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2253-2-5.anc" start="824" end="834" sStart="null" offset="262" sid="r10.particular.j.0296" wn="3" wnkey="particular%5:00:00:uncommon:00" text="Other papers in this series have described the application of PKQuest to propranolol, D 2 O, ethanol, inulin and protein bound antibiotics [ 1 2 3 ] . This paper will describe the application of PKQuest to volatile solutes, with particular emphasis on anesthetics." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2253-2-5.anc" start="20526" end="20531" sStart="null" offset="30" sid="r9.paper.n.0773" wn="5" wnkey="paper%1:10:02::" text="All the figures shown in this paper are copied directly from the standard PKQuest output." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2253-2-5.anc" start="5555" end="5560" sStart="null" offset="159" sid="r9.paper.n.0561" wn="5" wnkey="paper%1:10:02::" text="There have been no previous attempts to use a PBPK to model multiple, simultaneously measured anesthetics such as is described in this paper." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2253-2-5.anc" start="1739" end="1744" sStart="null" offset="76" sid="r9.paper.n.0343" wn="5" wnkey="paper%1:10:02::" text="The new approach for the volatile solutes that is developed in this paper is to assume that the tissue partition of these solutes is determined entirely by a) the oil/water partition coefficient and b) the fraction of lipid in the blood and each organ i (klip [i])." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2253-2-5.anc" start="36466" end="36472" sStart="null" offset="6" sid="r9.normal.j.0517" wn="1" wnkey="normal%3:00:01::" text="Thus, normal values of perfusion-ventilation mismatch have no significant effect on the uptake and washout of enflurane." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2253-2-5.anc" start="36333" end="36339" sStart="null" offset="60" sid="r9.normal.j.0926" wn="2" wnkey="normal%3:00:02::" text="It can be seen that the 16 compartment model with normal sig_v and sig_f (red) is almost indistinguishable from the homogeneous 1 compartment model (black)." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2253-2-5.anc" start="52265" end="52271" sStart="null" offset="63" sid="r9.normal.j.0214" wn="2" wnkey="normal%3:00:02::" text="Errors of this magnitude (13%) can be swamped by the normal variations in Kbair that result from variations in the blood fat content." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2253-2-5.anc" start="28234" end="28239" sStart="null" offset="472" sid="r9.level.n.0229" wn="1" wnkey="level%1:07:00::" text="Some of the most comprehensive and sophisticated human PBPKs have been developed to describe the pharmacokinetics of volatile toxic solvents such as toluene [ 32 44 45 ] , styrene [ 46 47 ] , and methyl chloride [ 48 ] . The most involved models incorporate several different fat and muscle compartments with different flows and allow for changes with time in the blood flows as the subject's exercise level varies [ 45 47 48 ] . These studies have also introduced a Bayesian approach to determine the population distribution of the PBPK parameters [ 45 47 ] . PKQuest cannot complete with these PBPKs for this class of solutes." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2253-2-5.anc" start="10633" end="10639" sStart="null" offset="140" sid="r9.level.n.0966" wn="1" wnkey="level%1:07:00::" text="(at a total inhaled concentration of less than 2%) and then washed them out while maintaining constant N 2 O levels." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2253-2-5.anc" start="30782" end="30790" sStart="null" offset="10" sid="r11.function.n.0709" wn="1" wnkey="function%1:24:00::" text="The input function was a 2 hour inhalation of toluene at a constant gas concentration of 2 ?M." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2253-2-5.anc" start="3423" end="3427" sStart="null" offset="76" sid="r9.fold.v.0925" wn="2147483645" wnkey="null" text="In addition, using the same set of parameters to fit the roughly 20 fold difference in concentration between the Munson et al." />
    <s path="file:/C:/OANC/data/written_2/technical/biomed/1471-2253-2-5.anc" start="49661" end="49669" sStart="null" offset="0" sid="null" wn="4" wnkey="exercise%2:29:00::" text="However, when these same subjects begin to &lt;b&gt;exercise&lt;/b&gt;, increasing the ventilatory rate by a factor of 2.5, the arterial and end tidal gas concentrations become approximately equal [ 67 ] . Presumably, at the higher rates of ventilation, there is relatively less time for exchange with the airways, and the artifact decreases." />
    <s path="file:/C:/OANC/data/written_2/technical/biomed/1471-2253-2-5.anc" start="49661" end="49669" sStart="null" offset="0" sid="null" wn="4" wnkey="exercise%2:29:00::" text="However, when these same subjects begin to &lt;b&gt;exercise&lt;/b&gt;, increasing the ventilatory rate by a factor of 2.5, the arterial and end tidal gas concentrations become approximately equal [ 67 ] . Presumably, at the higher rates of ventilation, there is relatively less time for exchange with the airways, and the artifact decreases." />
    <s path="file:/C:/OANC/data/written_2/technical/biomed/1471-2253-2-5.anc" start="49661" end="49669" sStart="null" offset="0" sid="null" wn="4" wnkey="exercise%2:29:00::" text="However, when these same subjects begin to &lt;b&gt;exercise&lt;/b&gt;, increasing the ventilatory rate by a factor of 2.5, the arterial and end tidal gas concentrations become approximately equal [ 67 ] . Presumably, at the higher rates of ventilation, there is relatively less time for exchange with the airways, and the artifact decreases." />
    <s path="file:/C:/OANC/data/written_2/technical/biomed/1471-2253-2-5.anc" start="49661" end="49669" sStart="null" offset="0" sid="null" wn="4" wnkey="exercise%2:29:00::" text="However, when these same subjects begin to &lt;b&gt;exercise&lt;/b&gt;, increasing the ventilatory rate by a factor of 2.5, the arterial and end tidal gas concentrations become approximately equal [ 67 ] . Presumably, at the higher rates of ventilation, there is relatively less time for exchange with the airways, and the artifact decreases." />
    <s path="file:/C:/OANC/data/written_2/technical/biomed/1471-2253-2-5.anc" start="49661" end="49669" sStart="null" offset="0" sid="null" wn="4" wnkey="exercise%2:29:00::" text="However, when these same subjects begin to &lt;b&gt;exercise&lt;/b&gt;, increasing the ventilatory rate by a factor of 2.5, the arterial and end tidal gas concentrations become approximately equal [ 67 ] . Presumably, at the higher rates of ventilation, there is relatively less time for exchange with the airways, and the artifact decreases." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2253-2-5.anc" start="28225" end="28233" sStart="null" offset="0" sid="null" wn="1" wnkey="physical_exercise%1:04:00::" text="Some of the most comprehensive and sophisticated human PBPKs have been developed to describe the pharmacokinetics of volatile toxic solvents such as toluene [ 32 44 45 ] , styrene [ 46 47 ] , and methyl chloride [ 48 ] . The most involved models incorporate several different fat and muscle compartments with different flows and allow for changes with time in the blood flows as the subject's &lt;b&gt;exercise&lt;/b&gt; level varies [ 45 47 48 ] . These studies have also introduced a Bayesian approach to determine the population distribution of the PBPK parameters [ 45 47 ] . PKQuest cannot complete with these PBPKs for this class of solutes." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2253-2-5.anc" start="28225" end="28233" sStart="null" offset="0" sid="null" wn="1" wnkey="physical_exercise%1:04:00::" text="Some of the most comprehensive and sophisticated human PBPKs have been developed to describe the pharmacokinetics of volatile toxic solvents such as toluene [ 32 44 45 ] , styrene [ 46 47 ] , and methyl chloride [ 48 ] . The most involved models incorporate several different fat and muscle compartments with different flows and allow for changes with time in the blood flows as the subject's &lt;b&gt;exercise&lt;/b&gt; level varies [ 45 47 48 ] . These studies have also introduced a Bayesian approach to determine the population distribution of the PBPK parameters [ 45 47 ] . PKQuest cannot complete with these PBPKs for this class of solutes." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2253-2-5.anc" start="28078" end="28087" sStart="null" offset="316" sid="r8.1.different.j.0361" wn="1" wnkey="different%3:00:00::" text="Some of the most comprehensive and sophisticated human PBPKs have been developed to describe the pharmacokinetics of volatile toxic solvents such as toluene [ 32 44 45 ] , styrene [ 46 47 ] , and methyl chloride [ 48 ] . The most involved models incorporate several different fat and muscle compartments with different flows and allow for changes with time in the blood flows as the subject's exercise level varies [ 45 47 48 ] . These studies have also introduced a Bayesian approach to determine the population distribution of the PBPK parameters [ 45 47 ] . PKQuest cannot complete with these PBPKs for this class of solutes." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2253-2-5.anc" start="1644" end="1653" sStart="null" offset="169" sid="r8.1.different.j.0023" wn="5" wnkey="different%5:00:01:other:00" text="This is accomplished by preprogramming a &quot;standard human&quot; data set that contains most of the information that is required to model the different solutes." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2253-2-5.anc" start="1644" end="1653" sStart="null" offset="169" sid="r8.1.different.j.0023" wn="1" wnkey="different%3:00:00::" text="This is accomplished by preprogramming a &quot;standard human&quot; data set that contains most of the information that is required to model the different solutes." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2253-2-5.anc" start="1644" end="1653" sStart="null" offset="169" sid="r8.1.different.j.0023" wn="1" wnkey="different%3:00:00::" text="This is accomplished by preprogramming a &quot;standard human&quot; data set that contains most of the information that is required to model the different solutes." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2253-2-5.anc" start="1644" end="1653" sStart="null" offset="169" sid="r8.1.different.j.0023" wn="5" wnkey="null" text="This is accomplished by preprogramming a &quot;standard human&quot; data set that contains most of the information that is required to model the different solutes." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2253-2-5.anc" start="9086" end="9098" sStart="null" offset="136" sid="r11.combination.n.0445" wn="1" wnkey="combination%1:14:00::" text="Although PKQuest uses only Kwair (water/air partition), Kfwat and klip[i] for the actual calculations, a variety of combinations of Kfwat, Kwair, Kbair (blood/air partition), Kbwat (blood/water partition), etc. can be entered." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2253-2-5.anc" start="50122" end="50129" sStart="null" offset="0" sid="null" wn="1" wnkey="become%2:30:00::" text="This suggests that solutes such as methoxyflurane or toluene are right on the boundary of where this artifact &lt;b&gt;becomes&lt;/b&gt; important." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2253-2-5.anc" start="50122" end="50129" sStart="null" offset="0" sid="null" wn="1" wnkey="become%2:30:00::" text="This suggests that solutes such as methoxyflurane or toluene are right on the boundary of where this artifact &lt;b&gt;becomes&lt;/b&gt; important." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2253-2-5.anc" start="36728" end="36734" sStart="null" offset="0" sid="null" wn="1" wnkey="become%2:30:00::" text="It is not until the normal values of sig_v and sig_f are increased by a factor of about 3 that differences &lt;b&gt;become&lt;/b&gt; significant." />
  </sentences>
</list>